These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24264883)

  • 1. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
    Krajewski KM; Nishino M; Franchetti Y; Ramaiya NH; Van den Abbeele AD; Choueiri TK
    Cancer; 2014 Mar; 120(5):711-21. PubMed ID: 24264883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
    Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
    Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
    Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
    Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymic measurements in pathologically proven normal thymus and thymic hyperplasia: intraobserver and interobserver variabilities.
    Araki T; Sholl LM; Gerbaudo VH; Hatabu H; Nishino M
    Acad Radiol; 2014 Jun; 21(6):733-42. PubMed ID: 24809315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
    Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
    AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical outcomes of antiangiogenic-targeted therapy in patients with pulmonary metastatic renal cell carcinoma using non-contrast-enhanced computed tomography.
    Wu GY; Suo ST; Kong W; Jin D; Zhang J; Xu JR
    Acad Radiol; 2014 Nov; 21(11):1434-40. PubMed ID: 25097010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.
    Nishino M; Guo M; Jackman DM; DiPiro PJ; Yap JT; Ho TK; Hatabu H; Jänne PA; Van den Abbeele AD; Johnson BE
    Acad Radiol; 2011 Jan; 18(1):54-62. PubMed ID: 21036632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interobserver and intraobserver variability of RECIST assessment in ovarian cancer.
    Krasovitsky M; Lee YC; Sim HW; Chawla T; Moore H; Moses D; Baker L; Mandel C; Kielar A; Hartery A; O'Malley M; Friedlander M; Oza AM; Wang L; Lheureux S; Wilson M
    Int J Gynecol Cancer; 2022 May; 32(5):656-661. PubMed ID: 35379690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT.
    Brufau BP; Cerqueda CS; Villalba LB; Izquierdo RS; González BM; Molina CN
    Radiographics; 2013 Oct; 33(6):1691-716. PubMed ID: 24108558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.
    Han KS; Jung DC; Choi HJ; Jeong MS; Cho KS; Joung JY; Seo HK; Lee KH; Chung J
    Cancer; 2010 May; 116(10):2332-42. PubMed ID: 20225226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
    Williams R; Hudson JM; Lloyd BA; Sureshkumar AR; Lueck G; Milot L; Atri M; Bjarnason GA; Burns PN
    Radiology; 2011 Aug; 260(2):581-90. PubMed ID: 21555352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
    Smith AD; Lieber ML; Shah SN
    AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
    AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.
    Thiam R; Fournier LS; Trinquart L; Medioni J; Chatellier G; Balvay D; Escudier B; Dromain C; Cuenod CA; Oudard S
    Ann Oncol; 2010 May; 21(5):936-41. PubMed ID: 19889607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
    Erasmus JJ; Gladish GW; Broemeling L; Sabloff BS; Truong MT; Herbst RS; Munden RF
    J Clin Oncol; 2003 Jul; 21(13):2574-82. PubMed ID: 12829678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra- and interobserver variability in CT measurements in oncology.
    McErlean A; Panicek DM; Zabor EC; Moskowitz CS; Bitar R; Motzer RJ; Hricak H; Ginsberg MS
    Radiology; 2013 Nov; 269(2):451-9. PubMed ID: 23824993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.
    Suzuki C; Torkzad MR; Jacobsson H; Aström G; Sundin A; Hatschek T; Fujii H; Blomqvist L
    Acta Oncol; 2010 May; 49(4):509-14. PubMed ID: 20397778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.